HCC
Clinical trials for HCC explained in plain language.
Never miss a new study
Get alerted when new HCC trials appear
Sign up with your email to follow new studies for HCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for liver cancer patients after immunotherapy fails
Disease control OngoingThis study tests the drug cabozantinib in 20 adults with advanced liver cancer that no longer responds to immunotherapy. The goal is to see if cabozantinib can slow tumor growth and extend survival. Participants take a daily pill, and researchers monitor side effects and disease …
Matched conditions: HCC
Phase: PHASE2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
New hope for liver cancer: immune-boosting drug targets hepatitis b patients
Disease control OngoingThis study tests a drug called pembrolizumab in 30 people with liver cancer caused by hepatitis B. The drug helps the immune system fight cancer. Researchers will check if tumors shrink and how the immune system changes during treatment. Participants must have stable hepatitis B …
Matched conditions: HCC
Phase: PHASE2 • Sponsor: CCTU • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control OngoingThis early-phase study tests a new treatment for people with advanced liver cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, modified to target a protein called IL1RAP on cancer cells. The main goals are to check safety and f…
Matched conditions: HCC
Phase: PHASE1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Custom-Made DNA vaccine takes on advanced liver cancer
Disease control OngoingThis study tests a personalized DNA vaccine (made from a patient's own tumor mutations) combined with an immune booster and an immunotherapy drug (pembrolizumab) in 36 adults with advanced liver cancer (HCC). The goal is to see if the vaccine is safe and can train the immune syst…
Matched conditions: HCC
Phase: PHASE1, PHASE2 • Sponsor: Geneos Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for advanced liver cancer: experimental drug faces off against standard therapy
Disease control OngoingThis study tests a new drug called pracytarabine against the standard drug regorafenib in people with advanced liver cancer that has not responded to targeted therapy or immunotherapy. About 60 adults aged 18-75 with good liver function are taking part. The goal is to see if prac…
Matched conditions: HCC
Phase: PHASE2, PHASE3 • Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd. • Aim: Disease control
Last updated May 18, 2026 12:02 UTC